#AskDrDurie: Is there a test available for measuring Minimal Residual Disease (MRD)?
In this week's #AskDrDurie, the IMF's Dr. Brian G.M. Durie answers a very important question regarding the tests available for measuring Minimal Residual Disease. As you may know, the IMF's Black Swan Research Initiative(R) has been evaluating a new flow test method for this, and it is becoming a new benchmark.
Dr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.